Journal of Shanghai Jiao Tong University (Medical Science) >
A novel antithrombotic antibody targeting the binding sites of the coagulation factor FⅨa-FⅧa complex
Received date: 2021-03-09
Online published: 2021-08-24
Supported by
National Natural Science Foundation of China(81970123);Innovative Research Team of High-level Local Universities in Shanghai(SSMU-ZDCX20180101)
·To prepare a monoclonal antibody targeting coagulation factor Ⅸa (FⅨa), a key factor in endogenous coagulation pathways, and study its antithrombotic roles and mechanisms.
·Immunization of mice, hybridoma technology, cell expression and purification were used to prepare the anti-FⅨa monoclonal antibodies of high purity. The monoclonal antibodies with high affinity for FⅨa were screened by enzyme-linked immunosorbent assay. The activated partial thromboplastin time (APTT) and prothrombin time (PT) were used to evaluate the antithrombotic effects of the monoclonal antibody. And then chromogenic substrate method was used to detect the effect of monoclonal antibody on the enzyme activity of FⅨa. The method of computer simulation of protein-protein docking was adopted to predict the possible binding sites between FⅨa and the antibody, and the binding site, was verified by competitive experiments (indirectly through the chromatic substrate method).
·FⅨa-4, an anti-FⅨa monoclonal antibody with high affinity, was generated. Although FⅨa-4 did not affect PT and the enzyme activity of FⅨa, it significantly prolonged APTT to 88.8 s, which was 3.5 times of the control group (25.5 s), in a concentration-gradient dependence. The protein-protein docking prediction results revealed that FⅨa-4 did not directly bind to substrate catalytic sites of FⅨa, but occupied the binding region of FⅨa and FⅧa. Competitive experiments further verified the above results. FⅨa-4 inhibited FⅩa production in a dose-dependent manner, almost completely inhibiting FⅩa production at the concentrations of 400 pmol/L, and FⅧa could correct the inhibition effect of the antibody up to nearly 50%.
·The monoclonal antibody against FⅨa-4 is obtained. FⅨa-4 competes with FⅧa to bind FⅨa, and inhibits the conversion of FⅩ to FⅩa which is catalyzed by FⅧa-FⅨa complex; it plays an antithrombotic role mainly by inhibiting endogenous coagulation pathway.
Tian-yao SUN , Shi-feng JIANG , Qin XU , Jun-ling LIU , Su-ying DANG , Xue-mei FAN . A novel antithrombotic antibody targeting the binding sites of the coagulation factor FⅨa-FⅧa complex[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2021 , 41(9) : 1133 -1141 . DOI: 10.3969/j.issn.1674-8115.2021.09.001
| 1 | 张珀, 邓云, 桂阳, 等. 抗血栓药物作用机制的研究进展[J]. 基层医学论坛, 2020, 24(25): 3682-3685. |
| 2 | Tscharre M, Michelson AD, Gremmel T. Novel antiplatelet agents in cardiovascular disease[J]. J Cardiovasc Pharmacol Ther, 2020, 25(3): 191-200. |
| 3 | 刘莅欣, 胡桃红. 血栓性疾病抗栓治疗的研究进展[J]. 中国临床医生, 2013, 41(5): 15-17. |
| 4 | 徐亭亭, 石慧, 王平保, 等. 靶向凝血因子的新型口服抗凝药物研究进展[J]. 中国药物化学杂志, 2020, 30(10): 636-642. |
| 5 | 孙思, 赵爱民. 复发性流产常用抗凝及抗血小板药物妊娠期暴露的安全性[J]. 上海交通大学学报(医学版), 2020, 40(3): 402-407. |
| 6 | 陈一竹, 张俊峰. 抗血小板治疗新靶点: 糖蛋白Ⅵ[J]. 上海交通大学学报(医学版), 2015, 35(7): 1078-1081. |
| 7 | Topol EJ. Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence[J]. Circulation, 1998, 97(2): 211-218. |
| 8 | Adeboyeje G, Sylwestrzak G, Barron JJ, et al. Major bleeding risk during anticoagulation with warfarin, dabigatran, apixaban, or rivaroxaban in patients with nonvalvular atrial fibrillation[J]. J Manag Care Specialty Pharm, 2017, 23(9): 968-978. |
| 9 | Toomey JR, Smith KJ, Stafford DW. Localization of the human tissue factor recognition determinant of human factor Ⅶa[J]. J Biol Chem, 1991, 266(29): 19198-19202. |
| 10 | 余婷. 刺囊酸, 皂皮酸及金合欢酸内酯的合成研究[D]. 南昌: 江西师范大学, 2019. |
| 11 | Misenheimer TM, Yang BY, Sheehan JP. The heparin-binding exosite is critical to allosteric activation of factor Ⅸa in the intrinsic tenase complex: the role of arginine 165 and factor Ⅹ[J]. Biochemistry, 2007, 46(26): 7886-7895. |
| 12 | Spanier TB, Chen JM, Oz MC, et al. Selective anticoagulation with active site-blocked factor Ⅸa suggests separate roles for intrinsic and extrinsic coagulation pathways in cardiopulmonary bypass[J]. J Thorac Cardiovasc Surg, 1998, 116(5): 860-869. |
| 13 | Lawson JH, Mann KG. Cooperative activation of human factor Ⅸ by the human extrinsic pathway of blood coagulation[J]. J Biol Chem, 1991, 266(17): 11317-11327. |
| 14 | Hoffman M, Monroe DM, Oliver JA, et al. Factors Ⅸa and Ⅹa play distinct roles in tissue factor-dependent initiation of coagulation[J]. Blood, 1995, 86(5): 1794-1801. |
| 15 | Butenas S, Orfeo T, Gissel MT, et al. The significance of circulating factor Ⅸa in blood[J]. J Biol Chem, 2004, 279(22): 22875-22882. |
| 16 | Boisclair MD, Lane DA, Philippou H, et al. Thrombin production, inactivation and expression during open heart surgery measured by assays for activation fragments including a new ELISA for prothrombin fragment F1+2[J]. Thromb Haemost, 1993, 70(2): 253-258. |
| 17 | Lollar P, Fass DN. Inhibition of activated porcine factor Ⅸ by dansyl-glutamyl-glycyl-arginyl-chloromethylketone[J]. Arch Biochem Biophys, 1984, 233(2): 438-446. |
| 18 | Benedict CR, Ryan J, Wolitzky B, et al. Active site-blocked factor Ⅸa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model[J]. J Clin Invest, 1991, 88(5): 1760-1765. |
| 19 | Walsh PN. Roles of factor Ⅺ, platelets and tissue factor-initiated blood coagulation[J]. J Thromb Haemost, 2003, 1(10): 2081-2086. |
| 20 | Mathur A, Zhong D, Sabharwal AK, et al. Interaction of factor Ⅸa with factor Ⅷa. Effects of protease domain Ca2+ binding site, proteolysis in the autolysis loop, phospholipid, and factor Ⅹ[J]. J Biol Chem, 1997, 272(37): 23418-23426. |
| 21 | Lenting PJ, Christophe OD, Maat H, et al. Ca2+ binding to the first epidermal growth factor-like domain of human blood coagulation factor Ⅸ promotes enzyme activity and factor Ⅷ light chain binding[J]. J Biol Chem, 1996, 271(41): 25332-25337. |
| 22 | Smiley DA, Becker RC. Factor Ⅸa as a target for anticoagulation in thrombotic disorders and conditions[J]. Drug Discov Today, 2014, 19(9): 1445-1453. |
| 23 | Venkateswarlu D. Structural insights into the interaction of blood coagulation co-factor Ⅷa with factor Ⅸa: a computational protein-protein docking and molecular dynamics refinement study[J]. Biochem Biophys Res Commun, 2014, 452(3): 408-414. |
| 24 | Dunbar J, Krawczyk K, Leem J, et al. SAbPred: a structure-based antibody prediction server[J]. Nucleic Acids Res, 2016, 44(W1): W474-W478. |
| 25 | Brenke R, Hall DR, Chuang GY, et al. Application of asymmetric statistical potentials to antibody-protein docking[J]. Bioinformatics, 2012, 28(20): 2608-2614. |
| 26 | Verhoef D, Visscher KM, Vosmeer CR, et al. Engineered factor Ⅹa variants retain procoagulant activity independent of direct factor Ⅹa inhibitors[J]. Nat Commun, 2017, 8(1): 528. |
| 27 | Scheiflinger F, Dockal M, Rosing J, et al. Enhancement of the enzymatic activity of activated coagulation factor Ⅸ by anti-factor Ⅸ antibodies[J]. J Thromb Haemost, 2008, 6(2): 315-322. |
| 28 | Lu QY, Yang LK, Manithody C, et al. Molecular basis of the clotting defect in a bleeding patient missing the Asp-185 codon in the factor Ⅹ gene[J]. Thromb Res, 2014, 134(5): 1103-1109. |
| 29 | DeLano WL. The PyMOL molecular graphics system[J]. Protein Struct Funct Genet, 2002, 30: 442-454. |
| 30 | Xu YM, Cai C, Chandarajoti K, et al. Homogeneous low-molecular-weight heparins with reversible anticoagulant activity[J]. Nat Chem Biol, 2014, 10(4): 248-250. |
| 31 | Weitz JI, Buller HR. Direct thrombin inhibitors in acute coronary syndromes: present and future[J]. Circulation, 2002, 105(8): 1004-1011. |
| 32 | Choudhri TF, Hoh BL, Prestigiacomo CJ, et al. Targeted inhibition of intrinsic coagulation limits cerebral injury in stroke without increasing intracerebral hemorrhage[J]. J Exp Med, 1999, 190(1): 91-99. |
/
| 〈 |
|
〉 |